☆ 4.6 Letter

A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia

BRITISH JOURNAL OF HAEMATOLOGY (2019)

Get Full Text
Add to Collection

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 185, Issue 3, Pages 583-587

Publisher

WILEY
DOI: 10.1111/bjh.15563

Keywords

BI 811283; low-dose cytarabine; acute myeloid leukaemia; Aurora B kinase; phase I

Categories

Hematology

Funding

  1. Boehringer Ingelheim

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.